President Donald Trump told reporters outside the White House on Friday that he has no knowledge of a plan to remove Food and Drug Administration Commissioner Marty Makary, even as multiple outlets reported that the president had signed off on exactly that.
Asked about the swirling reports, Trump offered three words that left Makary's future no clearer than before: "I've been reading about it, but I know nothing about it." Pressed on whether he planned to install a new FDA head, Trump said "no, no" and described the situation as "nothing much."
The gap between the president's public nonchalance and the reporting behind the scenes is wide enough to drive a regulatory truck through. The Wall Street Journal reported Tuesday that Trump had pressured Makary to fast-track approval for flavored nicotine vapes, and that Makary pushed back. By Friday, the Journal reported that the resulting friction had pushed Trump to sign off on a plan to fire the commissioner, Fox News Digital reported.
The Journal's reporting did not stand alone for long. Newsmax noted that people familiar with the matter described the plan as not yet final and said it could still change. The reported disputes extended beyond vaping to include abortion-pill policy, vaccine decisions, and broader complaints about Makary's management and regulatory pace.
Just the News reported that unnamed White House sources told multiple outlets Makary is expected to leave the administration "in the near future," though it remained unclear whether he would be fired or depart voluntarily. The timing, too, was uncertain.
Breitbart cited UPI reporting that Trump "intends to fire" Makary because he is "frustrated with the agency," and noted that Makary's tenure has been marked by staff departures and outside criticism from healthcare and pharmaceutical groups.
White House spokesman Kush Desai offered a statement that neither confirmed nor denied the reports. "President Trump has assembled the most experienced and talented administration in history, an administration that continues to focus on delivering more historic victories for the American people," Desai said.
Makary, a former oncology surgeon, was confirmed as FDA commissioner in March 2025. In fewer than 14 months, he has managed to draw criticism from nearly every direction, pro-life groups, Big Pharma trade organizations, and health-freedom activists all have grievances, though they often point in opposite directions.
Pro-life activists have accused Makary of slow-walking a safety review for the abortion pill mifepristone. SBA Pro-Life America president Marjorie Dannenfelser called for his firing in blunt terms:
"This is a five-alarm crisis for the pro-life movement and for the GOP. The GOP cannot win without its base and simply will not get the enthusiasm that drives turnout without leadership from the top."
That is a pointed warning, and it comes at a moment when Trump is actively working to reshape the 2026 midterm landscape through endorsements and coalition management. Losing pro-life enthusiasm heading into a midterm year is the kind of quiet political erosion that rarely makes headlines but shows up on Election Day.
On the other flank, John Crowley, head of the Biotechnology Innovation Organization, condemned Makary's personnel decisions in a recent op-ed:
"Some of the administration's recent efforts to reform the federal government through aggressive and often indiscriminate personnel cuts have lacked the strategic insights necessary to modernize and reform our nation's health care agencies, especially the FDA."
So the biotech lobby wants more staffing and a friendlier regulatory hand. Pro-life groups want faster action on mifepristone. And the White House, if the Journal's reporting holds, wanted faster approval for flavored vapes. Makary, it seems, moved too slowly for everyone.
Not everyone wants the commissioner gone. Several figures aligned with the Make America Healthy Again movement, the health-reform coalition championed by HHS Secretary Robert F. Kennedy Jr., spoke up forcefully on Makary's behalf.
Kelly Ryerson, an author and popular advocate known as Glyphosate Girl, told Fox News Digital that Makary is an ally worth keeping:
"Dr. Makary is an ally in the MAHA movement. It is not surprising that his uncaptured approach to protecting human health has been met with the swamp calling for his firing. The criticism is that he didn't approve flavored vapes quickly enough. The mothers who don't want their kids smoking find that reasoning alarming."
That framing, casting the push to remove Makary as an industry-driven operation, found an even louder echo from Turning Point USA-affiliated podcaster Alex Clark. In a Friday post on X, Clark wrote that "the attacks against FDA Commissioner Marty Makary are coming from Big Pharma and the media outlets financially dependent on pharmaceutical advertising for survival."
Clark went further, calling Makary "one of the strongest representatives of the MAHA movement inside the federal government" and urging Trump not to replace him "with a pharma puppet." Food activist and prominent MAHA media figure Vani Hari wrote that a Makary ouster "would be a horrible move."
The internal divide is telling. It mirrors a broader tension within the Trump coalition between populist health reformers and industry-aligned interests, a fault line that has been visible in other recent clashes over the administration's willingness to enforce its own directives.
The reported trigger for the friction, flavored nicotine vape approvals, may sound narrow, but it touches a nerve. The Journal reported that Trump pressured Makary on the issue and that Makary resisted. Newsmax added that the disputes included fruit-flavored e-cigarettes from a company called Glas.
For the MAHA wing, this is a test of whether the administration will prioritize public health or corporate access. For industry critics, Makary's pace on approvals signals an FDA that remains too cautious. And for the White House, the question appears to be simpler: when the president asks for movement, he expects it.
That dynamic is not unique to the FDA. Across the administration, Trump has shown limited patience for appointees who resist direction, a management style that has produced both rapid results and periodic turbulence. Whether Makary's pushback reflects principled independence or bureaucratic inertia depends entirely on which faction you ask.
Fox News Digital contacted the White House, HHS, the FDA, BIO, and SBA Pro-Life America for additional comment. No responses beyond Desai's statement were reported.
As of Friday evening, no formal dismissal action had been confirmed. Trump's own words, "I know nothing about it", leave every possibility open. He could fire Makary next week. He could keep him indefinitely. The Journal's sources said the plan could still change, and Just the News noted that even the manner of departure remained unclear.
Makary's defenders in the MAHA movement see the commissioner as a rare uncaptured regulator willing to challenge pharmaceutical interests from inside the federal government. His critics on the pro-life side see a commissioner who has failed to act on one of their highest priorities. The biotech lobby sees an agency losing institutional capacity through careless personnel cuts.
What none of them dispute is that Makary's position is precarious. A commissioner confirmed barely a year ago now faces pressure from the left, the right, the industry he regulates, and, if the reporting is accurate, the man who appointed him. That is a difficult place to govern from, even in the best of times. And Washington in 2026 is not the best of times for anyone trying to hold a middle ground.
The president says he knows nothing about it. The reporting says otherwise. Somewhere between those two positions, Marty Makary waits to find out whether his job still exists.
When a president tells reporters he "knows nothing" about a story every major outlet is running, it usually means a decision hasn't been announced yet, not that one hasn't been made. The only question now is whether Trump decides his team's internal signals have gotten ahead of him, or whether Makary's defenders can make a case loud enough to change the outcome.
In Washington, the people who survive are rarely the ones caught between the president and his priorities. Makary may be principled. He may even be right. But in this administration, slow-walking the boss's agenda has never been a long-term career strategy.
